Navigation Links
Cell Biosciences Acquires Brightwell Technologies
Date:5/12/2011

SANTA CLARA, Calif., May 12, 2011 /PRNewswire/ -- Cell Biosciences, Inc. today announced that it has acquired Brightwell Technologies, Inc. of Ottawa, Ontario for approximately U.S. $9 million in cash.

Brightwell Technologies is the market leader in Micro-Flow Imaging (MFI), an analytical technique used to detect particles and aggregates in protein-based therapeutics. Because of high interest in protein aggregation expressed by the FDA and other regulatory agencies, Brightwell's MFI products have experienced widespread adoption by the world's largest pharmaceutical and biotechnology companies. Brightwell was founded in 2001 and employs approximately 30 people at its headquarters in Ottawa, Ontario. Brightwell's 2011 revenues are expected to be approximately U.S. $5 million.

The acquisition of Brightwell Technologies significantly strengthens Cell Biosciences' position in the high-growth protein therapeutics market. Cell Biosciences entered that market in October 2010, with the acquisition of Convergent Bioscience. Convergent's products for protein characterization are used by virtually every major producer of protein therapeutics. Because Brightwell's MFI products are targeted at the same customer set, this transaction is expected to fuel additional market penetration for both product lines.

Commenting on the transaction, Tim Harkness, President and Chief Executive Officer of Cell Biosciences, said, "Brightwell's MFI platform holds the leading position in an important emerging market, and represents a great strategic fit with existing Cell Biosciences products. This is our fourth acquisition in 18 months and it represents another important step in our plan to build a highly focused and differentiated protein analysis pure-play."

Peter Moore, President of Brightwell Technologies, added, "We are extremely pleased to be joining Cell Biosciences. This transaction creates exciting opportunities for our people, and the cultural fit between the two organizations is ideal. Cell Biosciences' worldwide commercial infrastructure will immediately take Brightwell's business to the next level."

In connection with the transaction, Cell Biosciences raised U.S. $13 million in a second tranche of its Series F Preferred Stock financing led by Essex Woodlands Health Ventures. Existing investors, including Novo A/S, Domain Associates, Latterell Venture Partners, Royal Bank of Canada, The Vertical Group and Lansing Brown Investments, LLC, also participated in the financing.

ABOUT CELL BIOSCIENCES

Cell Biosciences is a private life sciences company focused on defining the future of protein analysis. The Company develops instrumentation systems, software and assay products that help researchers better understand proteins for fundamental research, biotherapeutics production, biomarker discovery and personalized medicine. With an installed base of over 10,000 systems, its customers include leading research institutions, pharmaceutical and biotechnology companies worldwide. Cell Biosciences is headquartered in Santa Clara, California. For more information, visit www.cellbiosciences.com.


'/>"/>
SOURCE Cell Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ardea Biosciences to Present at Two Upcoming Investor Conferences
2. Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference
3. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
4. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
5. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
6. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
7. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
8. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
9. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
10. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
11. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jan. 17, 2017 The Global Nebulizers Market ... 8.2% over the next decade to reach approximately $1698.68 ... the market is witnessing include rapidly growing demand in ... advancements in nebulizer products and online marketing strategies by ... market is categorized into pneumatic nebulizers, ultrasonic nebulizers and ...
(Date:1/17/2017)... DUBLIN , Jan. 17, 2017  Jazz Pharmaceuticals ... first patient has been enrolled in a Phase 3 ... versus best supportive care (BSC) in the prevention of ... undergoing hematopoietic stem cell transplant (HSCT) who are at ... VOD.  The defibrotide clinical trial will be conducted across ...
(Date:1/17/2017)... -- According to a new market research report "Neural Network Software Market by ... and Region - Global Forecast to 2021" published by MarketsandMarkets, the market to ... at a Compound Annual Growth Rate (CAGR) of 33.2%. ... ... ...
Breaking Medicine Technology:
(Date:1/17/2017)... Florida (PRWEB) , ... January 17, 2017 , ... Kevin ... Producers of AsSeenOnTV.pro will be featuring DRTV campaigns regarding the topic of Beauty and ... become a better version of themselves. What better way to commit to these changes ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, ... highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, ... this elite group of providers. , Produced by Zeltiq, CoolSculpting is approved by ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... joined the Peoples Health network on Dec. 1, 2016. Peoples Health, a ... Senior Medical Center is an exciting addition to our provider network, and the ...
(Date:1/17/2017)... OAKLAND, CA (PRWEB) , ... January 17, 2017 , ... ... been named winners of the fourth Cradle to Cradle Product Design Challenge , ... the fourth in a series of six circular design challenges scheduled to run through ...
Breaking Medicine News(10 mins):